For instance, with the progression of clinical stage, GLP-1 signaling score decreased in most cancers, including ACC, BLCA, BRCA, ESCA, HNSC, KIRC, THCA and PAAD (Figures 5A–H), while the opposite trend was observed in STAD (Figure 5I). Here, GLP1R is linked to cancer.